Characterization of primary isolate-like variants of simian-human immunodeficiency virus
about
Recombinant gas vesicles from Halobacterium sp. displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle.Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationPostnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infantRegional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremiaHeterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells.A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERSBlockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensRecombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodiesQualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virusImmunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaqueNeutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
P2860
Q33317659-C45EBEDC-78A4-46B1-B300-BFDF2E567BBCQ33737656-55D12543-582C-427E-90A8-3FE508BF6BE6Q33835295-0AD0E1D7-CD0F-475C-8799-9C5092DB36B2Q33839402-E9040E2D-F58D-4F93-B46B-AF21519A2A71Q33842286-E546E384-09E5-448B-B795-2AE32662A39DQ33847697-D16B8511-8129-414D-9BC0-2B4F0349B904Q33850605-3A555B09-9579-4064-B13D-BBC9B57E360DQ33851802-08600A90-41DC-4D13-9135-93D017DB2FC1Q33852768-ED98F726-7570-4DCE-8C4E-5AE9061DCF99Q33941033-894B3771-21D5-487D-91F7-C056CBAB21B6Q34016706-F9E0281C-528D-4DE6-9F41-31F97DD5CA66Q34301874-953AA684-60E2-4D7A-9F45-33DD62D2AE7DQ34332009-499DDE1A-30AC-4E53-94A1-A7AC3FED31AEQ34344205-136396D7-4357-4447-B941-CD10C57C6A91Q34546037-95B1E367-7AD3-4F2D-895F-AA25EBCBC658Q35077039-5419C368-94BD-4874-9E3C-6986E2992C3BQ35123128-6EB18A1D-77F3-4537-A444-262E837E3E7BQ35155451-A1870AC6-636C-431C-A4FF-E1D3044DC828Q35690771-58F68DEA-D7C5-4233-80FF-C49DC22FEF1AQ35925858-943F1C1B-B6C7-4BCA-9755-E0428863AB65Q35973601-C66971F4-0EC8-4E15-AF0E-5597272E1531Q36138144-DEB1CEE4-6F9E-4759-B791-AAF015A127C8Q36141610-4F9D42DB-4306-4ABB-831A-0036B04F3596Q36525047-E4F21351-D5D6-423C-9875-86B85F12A482Q37009569-1C57AB86-8312-4038-B801-FAE9A63CA120Q37094160-7AF96D47-7BF0-4561-8AAC-380D7E57EF44Q37181874-066C036A-2BE5-4353-9C03-B7F9E234A846Q37547702-19AC9BD9-2A2D-45BC-BEF1-B1F578494D76Q37682968-D2439D6A-7FAD-46C5-804D-904F35D3B94FQ37683291-B6573AB5-4FB7-4748-9BC5-116DCCAC4BB5Q37742938-602771DD-321B-49F0-A3AD-D62A33E8C642Q39682485-420A4D09-6A7B-4E07-A010-B3F652F62BF1Q39699309-6C42D984-9872-4E8A-B7B9-42C95593F4B5Q42148035-B3CB4AE4-BC4A-4734-A85C-C91477FC1DE3Q47399269-2F7E5ADE-2C4D-457B-8F97-8BEAD61DB75DQ54209545-82EEC53D-1447-400F-B21E-93D68D590C6A
P2860
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@ast
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@en
type
label
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@ast
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@en
prefLabel
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@ast
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@en
P2093
P2860
P1433
P1476
Characterization of primary isolate-like variants of simian-human immunodeficiency virus
@en
P2093
D C Montefiori
D R Burton
J G Sodroski
J M Crawford
K A Reimann
K H Manson
P2860
P304
10199-10207
P577
1999-12-01T00:00:00Z